Vaccinia-based vaccines to biothreat and emerging viruses

References

• Akahata, W., Yang, Z.-Y., Andersen, H., Sun, S., Holdaway, H. A., Kong, W.-P., … Nabel, G. J. (2010). A virus-like particle vaccine for epidemic Chikungunya virus protects nonhuman primates against infection. Nature Medicine, 16(3), 334–338. doi:10.1038/nm.2105
   PubMed Web of Science ®Google Scholar
• Baur, K., Brinkmann, K., Schweneker, M., Patzold, J., Meisinger-Henschel, C., Hermann, J., … Hausmann, J. (2010). Immediate-early expression of a recombinant antigen by modified vaccinia virus ankara breaks the immunodominance of strong vector-specific B8R antigen in acute and memory CD8 T-cell responses. Journal of Virology, 84(17), 8743–8752.10.1128/JVI.00604-10
   PubMed Web of Science ®Google Scholar
• Clark, R. H., Kenyon, J. C., Bartlett, N. W., Tschake, D. C., & Smith, G. L. (2006). deletion of A41L enhances vaccinia virus immunogenicity and vaccine efficacy. Journal of General Virology, 87, 29–38.10.1099/vir.0.81417-0
   PubMed Web of Science ®Google Scholar
• Cottingham, M. G., & Carroll, M. W. (2013). Recombinant MVA vaccines: Dispelling the myths. Vaccine, 31, 4247–4251. doi:10.1016/j.vaccine.2013.03.021
   PubMed Web of Science ®Google Scholar
• van den Doel, P., Volz, A., Roose, J. M., Sewbalaksing, V. D., Pijlman, G. P., van Middelkoop, I., … Martina, B. E. E. (2014). Recombinant modified vaccinia virus Ankara expressing glycoprotein E2 of chikungunya virus protects AG129 mice against lethal challenge. PLoS Neglected Tropical Diseases, 8(9), e3101. doi:10.1371/journal.pntd.0003101
   PubMed Web of Science ®Google Scholar
• Eldi, P., Cooper, T. H., Lui, L., Prow, N. A., Diener, K. R., Howley, P. M., … Hayball, J. D. (2017). Production of a chikungunya vaccine using a CHO cell and attenuated viral-based platform technology. Molecular Therapy, 25(10). doi:10.1016/j.ymthe.2017.06.017
   PubMed Web of Science ®Google Scholar
• Ferrier-Rembert, A., Drillien, R., Tournier, J. N., Garin, D., & Crance, J. M. (2008). Short and long- term immunogenicity and protection induced by non-replicating smallpox vaccine candidates in mice and comparison with the traditional 1st generation vaccine. Vaccine, 26, 1794–1804. doi:10.1016/j.vaccine.2007.12.059
   PubMed Web of Science ®Google Scholar
• Frey, S. E., Winokur, P. L., Hill, H., Goll, J. B., Chaplin, P., & Belshe, R. B. (2014). Phase II randomized, double-blinded comparison of a single high dose (5×108 TCID50) of modified vaccinia Ankara compared to a standard dose (1×108 TCID50) in healthy vaccinia-naïve individuals. Vaccine, 32(23), 2732–2739.10.1016/j.vaccine.2014.02.043
   PubMed Web of Science ®Google Scholar
• Fuerst, T. R., Fernandez, M. P., & Moss, B. (1987). Transfer of the inducible lac repressor/operator system from Escherichia coli to a vaccinia virus expression vector. Proceedings of the National Academy of Sciences of the United States of America, 86, 2549–2553.
   Web of Science ®Google Scholar
• Fuerst, T. R., Earl, P. L., & Moss, B. (1989). Use of a hybrid vaccinia virus-T7 RNA polymerase system for expression of target genes. Molecular and Cellular Biology, 7, 2538–2544.10.1128/MCB.7.7.2538
   Web of Science ®Google Scholar
• Garcia-Arriaza, J., Cepeda, V., Hallengard, D., Sorzano, C. O. S., Kummerer, B. M., Liljestrom, P., & Esteban, M. (2014). A novel poxvirus-based vaccine, MVA-CHIKV, is highly immunogenic and protects mice against chikungunya infection. Journal of Virology, 88(6), 3527–3547.10.1128/JVI.03418-13
   PubMed Web of Science ®Google Scholar
• García-Arriaza, J., & Esteban, M. (2014). Enhancing poxvirus vectors vaccine immunogenicity. Human Vaccines & Immunotherapeutics, 10(8), 2235–2244.10.4161/hv.28974
   PubMed Web of Science ®Google Scholar
• García-Arriaza, J., Arnáez, P., Gόmez, C., Sorzano, C. O. S., & Esteban, M. (2013). Improving adaptive and memory immune responses of an HIV/AIDS vaccine candidate MVA-B by Deletion of vaccinia virus genes (C6L and K7R) blocking interferon signaling pathways. PLoS ONE, 8, e66894. doi:10.1371/journal.pone.0066894
   PubMed Web of Science ®Google Scholar
• García-Arriaza, J., Perdiguero, B., Heeney, J., Seaman, M., Montefiori, D. C., Labranche, C., … Esteban, M. (2015). Head-to-head comparison of poxvirus NYVAC and ALVAC vectors expressing identical HIV-1 clade C immunogens in prime-boost combination with env protein in nonhuman primates. Journal of Virology, 89, 8525–8539. doi:10.1128/JVI.01265-15
   PubMed Web of Science ®Google Scholar
• Gómez, C.E., Perdiguero, B., García-Arriaza, J., & Esteban, M. (2013). Clinical applications of attenuated MVA poxvirus strain. Expert Review of Vaccines, 12, 1395–1416.10.1586/14760584.2013.845531
   PubMed Web of Science ®Google Scholar
• Greenberg, R. N., Hurley, M. Y., Dinh, D. V., Mraz, S., Vera, J. G., von Bredow, D., … Chaplin, P. (2015). A multicenter, open-label, controlled phase II study to evaluate safety and immunogenicity of MVA smallpox vaccine (IMVAMUNE) in 18–40 year old subjects with diagnosed atopic dermatitis. PLoS ONE, 10(10), e0138348.10.1371/journal.pone.0138348
   PubMed Web of Science ®Google Scholar
• Griffin, D. E. (2013). Alphaviruses. In D. M. Knipe & P. M. Howley (Eds.), Fields virology (6th ed., pp. 651–686). New York, NY: Wolters Kluwer Health/Lippincott Williams & Wilkins.
   Google Scholar
• Gόmez, C. E., Najera, J. L., Krupa, M., Perdiguero, B., & Esteban, M. (2011). MVA and NYVAC as vaccines against emergent infectious diseases and cancer. Current Gene Therapy, 11(3), 189–217.10.2174/156652311795684731
   PubMed Web of Science ®Google Scholar
• Haddad, D. (2017). Genetically engineered vaccinia viruses as agents for cancer treatment, imaging, and transgene delivery. Frontiers Oncology, 7, 96. doi:10.3389/fonc.2017.00096
   Web of Science ®Google Scholar
• Harrop, R., John, J., & Carroll, M. W. (2006). Recombinant viral vectors: Cancer vaccines. Advanced Drug Delivery Reviews, 58(8), 931–947.10.1016/j.addr.2006.05.005
   PubMed Web of Science ®Google Scholar
• Hu, W.-G., Kalla, M., Volkmann, A., Noll, D., Steigerwald, R., & Nagata, L. P. (2017). Protective efficacy of monovalent recombinant MVA vaccines against threee encephalitic alphaviruses (submitted for publication).
   Google Scholar
• Irwin, C. R., Hitt, M. M., & Evans, D. H. (2017). Targeting nucleotide biosynthesis: A strategy for improving the oncolytic potential of DNA viruses. Frontiers in Oncology, 7, 229. doi:10.3389/fonc.2017.00229
   Google Scholar
• Jackson, S. S., Ilyinkii, P., Philippon, V., Gritz, L., Goméz Yafal, A., Zinnack, K., … Panicali, D.L. (2005). Role of genes that modulate host immune responses in the immunogenicity and pathogenicity of vaccinia virus. Journal of Virology, 79, 6554–6559.10.1128/JVI.79.10.6554-6559.2005
   PubMed Web of Science ®Google Scholar
• Jonker, E. F. F., Visser, L. G., & Roukens, A. H. (2013). Advances and controversies in yellow fever vaccination. Therapeutic Advances in Vaccines, 1(4), 144–152.10.1177/2051013613498954
   PubMedGoogle Scholar
• Kibler, K. V., Gomez, C. E., Perdiguero, B., Wong, S., Huynh, T., Holechek, S., … Esteban, M. (2011). Improved NYVAC-based vaccine vectors. PLoS ONE, 6(11), e25674. doi:10.1371/journal.pone.0025674
   PubMed Web of Science ®Google Scholar
• Lauer, K.B., Borrow, R., & Blanchard, T.J. (2017). Multivalent and multipathogen viral vector vaccines. Clinical and Vaccine Immunology, 24, e00298-16. doi:10.1128/CVI.00298-16
   PubMed Web of Science ®Google Scholar
• Mayr, A., Stickl, H., Muller, H. K., Danner, K., & Singer, H. (1978). The smallpox vaccination strain MVA: Marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism (author’s transl). Zentralblatt für Bakteriologie, 167(5–6), 375–390.
   Google Scholar
• McCart, J. A., Ward, J. M., Lee, J., Hu, Y., Alexander, H. R., Libutti, S. K., … Barlett, D. L. (2001). Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes. Cancer Research, 61, 8751–8757.
   PubMed Web of Science ®Google Scholar
• Milligan, I. D., Gibani, M. M., Sewell, R., Clutterbuck, E. A., Campbell, D., Plested, E., … Snape, M. D. (2016). Safety and immunogenicity of novel adenovirus type 26- and modified vaccinia Ankara-vectored Ebola vaccines: A randomized clinical trial. JAMA, 315(15), 1610–1623. doi:10.1001/jama.2016.4218
   PubMed Web of Science ®Google Scholar
• Monath, T. P., & Vasconcelos, P. F. C. (2015). Yellow fever. Journal of clinical virology, 64, 160–173.
   PubMed Web of Science ®Google Scholar
• Nagata, L. P., Hu, W.-G., Steigerwald, R., Kalla, M., Irwin, C., Umer, B., … Evans, D. H. (2017, June 1–2). Vaccinia vaccines to biothreat and emerging viruses. Alberta Virology Conference, Edmonton, Canada, (presentation).
   Google Scholar
• Noyce, R. S., Lederman, S., & Evans, D. H. (2018). Construction of an infectious horsepox virus vaccine from chemically synthesized DNA fragments. PLoS One, 13(1), e0188453. doi: 10.1371/journal.pone.0188453.
   PubMed Web of Science ®Google Scholar
• Pabakaran, M., Leyrer, S., He, F., Auer, S., Kumar, S. R., Kindsmueller, K., … Kwang, J. (2014). Progress towards a universal H5N1 vaccine: A recombinant modeified vaccinia virus, Ankara-expressing trivalent hemagglutinin vaccine. PLoS One, 9(9), e107316. doi:10.1371/journal.pone.0107316
   PubMed Web of Science ®Google Scholar
• Potts, K. G., Irwin, C. R., Favis, N. A., Pink, D. B., Vincent, K. M., Lewis, J. D., … Evans, D. H. (2017). Deletion of F4L (ribonucleotide reductase), in vaccinia virus, produces a selective oncolytic virus and promotes anti-tumor immunity with superior safety in bladder cancer models. EMBO Molecular Medicine, 9(5), 638–654.10.15252/emmm.201607296
   PubMed Web of Science ®Google Scholar
• Raengsakulrach, B., Nisalak, A., Gettayacamin, M., Thirawuth, V., Young, G. D., Saw, K., … Vaughn, D. W. (1999). Safety, immunogenicity, and protective efficacy of NYVAC-JEV and ALVAC-JEV recombinant Japanese encephalitis vaccines in rhesus monkeys. The American Journal of Tropical Medicine and Hygiene, 60(3), 343–349.10.4269/ajtmh.1999.60.343
   PubMed Web of Science ®Google Scholar
• Ramsauer, K., & Tangy, F. (2016). Chikungunya vaccines: Viral vector-based approaches. Journal of Infectious Diseases, 214(Suppl 5), S500–S505.10.1093/infdis/jiw369
   PubMed Web of Science ®Google Scholar
• Russell, T.A., & Tscharke, D.C. (2014). Strikingly poor CD8(+) T-cell immunogenicity of vaccinia virus strain MVA in BALB/c mice. Immunology and Cell Biology, 92, 466–469. doi:10.1038/icb.2014.10
   PubMed Web of Science ®Google Scholar
• Sánchez-Sampedro, L., Perdiguero, B., Mejías-Pérez, E., Garcia-Arriara, J., Di Pilato, M., & Esteban, M. (2015). The evolution of poxvirus vaccines. Viruses, 7(4), 1726–1803.
   PubMed Web of Science ®Google Scholar
• Schäfer, B., Holzer, G.W., Joachimsthaler, A., Coulibaly, S., Schwendinger, M., Crowe, B.A., … Falkner, F. G. (2011). Pre-clinical efficacy and safety of experimental vaccines based on non-replicating vaccinia vectors against yellow fever. PLoS ONE, 6(9), e24505.10.1371/journal.pone.0024505
   PubMed Web of Science ®Google Scholar
• Schweneker, M., Laimbacher, A. S., Zimmer, G., Wager, S., Schraner, E. M., Wolferstätter, M., … Hausmann, J. (2017). Recombinant modified vaccinia virus Ankara generated Ebola virus-like particles. Journal of Virology, 91, e00343-17. doi:10.1128/JVI.00343-17
   PubMed Web of Science ®Google Scholar
• Smalley, C., Erasmus, J. H., Chesson, C. B., & Beasley, D. W. C. (2016). Status of research and development of vaccines for chikungunya. Vaccine, 34, 2976–2981.10.1016/j.vaccine.2016.03.076
   PubMed Web of Science ®Google Scholar
• Smith, G. L., Benfield, C. T., Maluquer de Motes, C., Mazzon, M., Ember, S. W., Ferguson, B. J., & Sumner, R. P. (2013). Vaccinia virus immune evasion: Mechanisms, virulence and immunogenicity. Journal of General Virology, 94, 2367–2392.10.1099/vir.0.055921-0
   PubMed Web of Science ®Google Scholar
• Sumner, R. P., Ren, H., Ferguson, B. J., & Smith, G. L. (2016). Increased attenuation but decreased immunogenicity by deletion of multiple vaccinia virus immunomodulators. Vaccine, 34(40), 4827–4834.10.1016/j.vaccine.2016.08.002
   PubMed Web of Science ®Google Scholar
• Sutter, G., & Staib, C. (2003). Vaccinia vectors as candidate vaccines: The development of modified vaccinia virus ankara for antigen delivery. Current Drug Target-Infectious Disorders, 3(3), 263–271.10.2174/1568005033481123
   PubMedGoogle Scholar
• Tartaglia, J., Perkus, M. E., Taylor, J., Norton, E. K., Audonnet, J.-C., Cox, W. I., … Paoletti, E. (1992). NYVAC: A highly attenuated strain of vaccinia virus. Virology, 188, 217–232.10.1016/0042-6822(92)90752-B
   PubMed Web of Science ®Google Scholar
• Tree, J. A., Hall, G., Rees, P., Vipond, J., Funnell, S. G., & Roberts, A. D. (2016). Repeated high-dose (5 x 10(8) TCID50) toxicity study of a third generation smallpox vaccine (IMVAMUNE) in New Zealand white rabbits. Human Vaccines Immunotherapeutics, 12(7), 1795–1801.
   PubMed Web of Science ®Google Scholar
• Tulman, E. R., Delhon, G., Afonso, C. L., Lu, Z., Zsak, L., Sandybaev, N. T., & Rock, D. L. (2006). Genome of horsepox virus. Journal of Virology, 80(18), 9244–9258.10.1128/JVI.00945-06
   PubMed Web of Science ®Google Scholar
• Valkenburg, S. A., Li, O. T. W., Mak, P. W. Y., Mok, C. K. P., Nicholls, J. M., Guan, Y., … Poon, L. L. M. (2014). IL-15 adjuvanted multivalent vaccinia-based universal influenza vaccine requires CD4+ T cells for heterosubtypic protection. Proceedings of the National Academy of Sciences, 111, 5676–5681.10.1073/pnas.1403684111
   PubMed Web of Science ®Google Scholar
• Vellozzi, C., Lane, J. M., Averhoff, F., Maurer, T., Norton, S., Damon, I. & Casey, C. (2005). Generalized vaccinia, progressive vaccinia, and eczema vaccinatum are rare following smallpox (vaccinia) vaccination: United States surveillance, 2003. In Henderson, D. A., Inglesby, T. V. Jr. & O’Toole, T. (2nd ed.), Confronting Biological Weapons. Clinical Infectious Diseases, 41, 689–697. 10.1086/432584
   Google Scholar
• Veyer, D. L., Carrara, G., Maluquer de Motes, C., & Smith, G. L. (2017). Vaccinia virus evasion of regulated cell death. Immunology Letters, 186, 68–80. doi:10.1016/j.imlet.2017.03.015
   PubMed Web of Science ®Google Scholar
• Vollmar, J., Arndtz, N., Eckl, K. M., Thomsen, T., Petzold, B., Mateo, L., … Chaplin, P. (2006). Safety and immunogenicity of IMVAMUNE, a promising candidate as a third generation smallpox vaccine. Vaccine, 24(12), 2065–2070.10.1016/j.vaccine.2005.11.022
   PubMed Web of Science ®Google Scholar
• von Krempelhuber, A., Vollmar, J., Pokorny, R., Rapp, P., Wulff, N., Petzold, B., … Kollaritsch H. (2010). A randomized, double-blind, dose-finding Phase II study to evaluate immunogenicity and safety of the third generation smallpox vaccine candidate IMVAMUNE®. Vaccine, 28(5), 1209–1216.10.1016/j.vaccine.2009.11.030
   PubMed Web of Science ®Google Scholar
• Weber, C., Bücher, S. M., & Schnierle, B. S. (2015). A small antigenic determinant of the chikungunya virus E2 protein is sufficient to induce neutralizing sntibodies which are partially protective in mice. PLOS Neglected Tropical Diseases, 9(4), e0003684. doi:10.1371/journal.pntd.0003684
   PubMed Web of Science ®Google Scholar
• Weger-Lucarelli, J., Chu, H., Aliota, M. T., Partidos, C. D., & Osorio, J. E. (2014). A novel MVA vectored chikungunya virus vaccine elicits protective immunity in mice. PLoS Neglected Tropical Diseases, 8(7), e2970. doi:10.1371/journal.pntd.0002970
   PubMed Web of Science ®Google Scholar
• Wennier, S. T., Brinkmann, K., Steinhäußer, C., Mayländer, N., Mnich, C., Wielert, U., … Steigerwald, R. (2013). A novel naturally occurring tandem promoter in modified vaccinia virus ankara drives very early gene expression and potent immune responses. PLoS ONE, 8(8), e73511.10.1371/journal.pone.0073511
   PubMed Web of Science ®Google Scholar
• Wyatt, L. S., Xiao, W., Americo, J. L., Earl, P. L., & Moss, B. (2017). Novel nonreplicating vaccinia virus vector enhances expression of heterologous genes and suppresses synthesis of endogenous viral proteins. mBio, 8, e00790-17. doi: 10.1128/mBio.00790-17
   Google Scholar
• Yao, X.D., & Evans, D.H. (2003). High-frequency genetic recombination and reactivation of orthopoxviruses from DNA fragments transfected into leporipoxvirus-infected cells. Journal of Virology, 77(13), 7281–7290.10.1128/JVI.77.13.7281-7290.2003
   PubMed Web of Science ®Google Scholar